Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3203734 | 0.99 | OPRM1 (0.51) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| SCHEMBL3211321 | 0.95 | OPRM1 (0.53) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL3214758 | 0.94 | OPRM1 (0.54) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| SCHEMBL3219971 | 0.88 | OPRL1 (0.51) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| SCHEMBL3210441 | 0.88 | OPRL1 (0.51) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL3222678 | 0.87 | OPRL1 (0.53) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| SCHEMBL3220333 | 0.87 | OPRM1 (0.56) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| Hydrochloric Acid SCHEMBL3214662 | 0.87 | OPRL1 (0.53) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| SCHEMBL3207969 | 0.87 | OPRM1 (0.56) | OPRM1OPRL1TAAR1OPRK1OPRD1 | |
| SCHEMBL3207955 | 0.87 | OPRM1 (0.64) | OPRM1OPRL1TAAR1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678834-B2 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2010-03-16 | — | — | US | claimed |
| EP-1406859-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-01-02 | — | — | EP | claimed |
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2004-10-28 | — | — | US | claimed |
| EP-1406859-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003008371-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | claimed |
| US-7678834-B2 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2010-03-16 | — | — | US | disclosed |
| EP-1406859-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | GRUENENTHAL GMBH (DE) | 2008-01-02 | — | — | EP | disclosed |
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | GRUENENTHAL GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1406859-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003008371-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANOL DERIVATIVES | Grünenthal GmbH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214822-A1 | Substituted 4-aminocyclohexanol compounds | ADRA2C, OPRD1, OPRK1 | OPRM1 6/4885OPRL1 4/4885TAAR1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.